Huntington's Disease Clinical Trials

Huntington's Disease studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect huntington's disease clinical trial.

Condition

Location

Distance

Age

Clinical Trials Huntington's Disease Clinical Trials

PTC518for Huntington Disease

Washington, United States

Washington, United States

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 and placebo in participants with HD.

Active TDCSfor Neurobehavioral Manifestations

Waitlist Available

The purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tDCS) to Huntingtons Disease (HD) patients in the early to middle stages and to assess the efficacy of tDCS for HD-related behavioral, cognitive and other symptoms

Movement To Musicfor Huntington Disease

The purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1). A secondary aim will be to determine if a movement to music exercise program delivered via telehealth improves balance, cognition, mobility, and quality of life (Aim 2).

MindTrailsfor Etat Marbre

Charlottesville, VA

Waitlist Available

Charlottesville, VA

The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.

Branaplamfor Huntington Disease

This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be efficacious over longer periods of time.

SAGE-718for Huntington Disease

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

WVE-003for Huntington Disease

This study is evaluating whether a drug called WVE-003 can slow the progression of Huntington's disease.

Deutetrabenazinefor Huntington Disease

Examine the effects of deutetrabenazine on functional speech and gait impairment

Pridopidinefor Huntington Disease

Vancouver, Canada

Waitlist Available

Vancouver, Canada

This study is evaluating whether a drug may help reduce symptoms of Huntington's disease.

Melatoninfor Huntington Disease

This study is evaluating whether melatonin may help improve sleep quality for individuals with Huntington's disease.

BioStamp NPoint Devicefor Huntington Disease

This study is evaluating whether risperidone may help reduce involuntary movements in individuals with Huntington's disease.

Intra-striatal RAAV5-miHTTfor Huntington Disease

This study is evaluating whether a drug may help reduce symptoms of Huntington's disease.

Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)for Huntington Disease

This study is evaluating whether a drug may help reduce irritability in individuals with Huntington's disease.

RO7234292 (RG6042)for Huntington Disease

Waitlist Available

This study is evaluating the long-term safety and tolerability of a drug that is being developed for Huntington's disease.

Nilotinib 150 MGfor Huntington Disease

Washington, United States

Waitlist Available

Washington, United States

This study is evaluating whether nilotinib may have positive impacts for individuals with Parkinson's disease.

RO7234292for Huntington Disease

Waitlist Available

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD).

Protocol Intervention Groupfor Huntington Disease

Phase A: Recruit 50 patients with HD, and their caregivers, to complete a neuropsychiatric and quality of life battery of scales at baseline. Have these 50 patients complete a formal psychiatric assessment with a psychiatrist within 2 weeks of this clinical battery, and the results of these 2 types of assessments will be compared to establish the level of agreement between clinical rating scales and formal psychiatric assessment. Phase B: Continue to follow Phase A cohort longitudinally and administer neuropsychiatric and quality of life battery at 6 months, 12 months, and 18 months form baseline. Recruit an additional 50 patients, administer the same neuropsychiatric and quality of life battery at baseline, implement medication and counseling intervention according to a standard of care protocol, and follow up with the same neuropsychiatric and quality of life battery at 6, 12, and 18 months.

Physical Activityfor Huntington Disease

Los Angeles, CA

Waitlist Available

Los Angeles, CA

Huntington's disease (HD) is a genetic, degenerative neurological disease that affects individuals in their third-fourth decade of life and individuals can live 15-20 years with manifest HD. The complex disease symptoms, including motor, cognitive and behavioural impairments, result in loss of functional independence and progressive escalation of healthcare costs. The personal, social and economic consequences of HD are devastating, especially as there are currently no disease modification therapies available. Environmental factors, including exercise and physical activity, have the potential to minimize the functional impact of HD. Animal models of HD have provided the first evidence that exercise has the potential to delay or alter disease progression. A range of studies in clinical populations have shown that short-term exercise (< 3 months) is well tolerated and has the potential to improve quality of life, fitness and motor impairments in HD. Despite these promising studies, there are critical knowledge gaps that prevent the intelligent application of exercise as a therapeutic intervention in HD. Firstly, there have been no prospective evaluations of the potential role of physical activity and exercise in disease modification in HD. To date, only retrospective data has suggested that lifestyle factors, including sedentary behavior, could negatively affect disease progression in HD. Secondly, it is not known if sustained exercise (> 3 months) is feasible, and if it has the potential to improve cognitive outcomes, such as has been shown in other neurodegenerative diseases. Such longer-term studies are essential to elucidate the potential for exercise to have a disease-modifying effect; the mechanisms through which such improvement may occur have yet to be explored. In this trial, the investigators will employ a systematic approach for routinely collecting prospective physical activity and fitness data and monitoring physical activity behaviour in 120 individuals with HD. The investigators will use a database to track physical activity and exercise behaviour alongside standardized disease-specific outcome measures during two annual visits. Assessment will incorporate VO2max, a surrogate measure of fitness and a direct measure of oxygen uptake related to central nervous system (CNS) function and structure, and the use of wearable technologies (Gene-activ activity monitors) that capture and quantify dose (frequency, duration, intensity) of physical activity in a large HD cohort. The investigators will further conduct a within-cohort randomized control trial (RCT) of a 12-month exercise intervention in HD, comparing a supported structured aerobic exercise training program to activity as usual. This intervention will also incorporate a physical activity coaching program developed and evaluated by our group with a view to encouraging longer term exercise uptake.

Retinal Imagingfor Neurodegenerative Diseases

Locally Advanced

This study is evaluating whether a new imaging technique can help detect early signs of neurodegenerative diseases.

Tetrabenazinefor Huntington Disease

This study is evaluating whether a medicine commonly used to treat Huntington's disease may help reduce impulsivity in individuals with the disease.

Far Infrared Radiationfor Huntington Disease

Toronto, Canada

Waitlist Available

Toronto, Canada

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Ursodiolfor Huntington Disease

Waitlist Available

The purpose of this study is to evaluate the safety of the drug ursodiol (ursodeoxycholic acid, UDCA) in people with Huntington's disease (HD) and to explore how the compound is processed by the body.

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Power

Back to top